Tag: Malaria Charity
-
Growing GiveWell’s Largest Research Area: Malaria
Despite significant progress fighting malaria over the past few decades, the disease still kills around 600,000 people annually. Malaria is a leading cause of death globally, especially for young children in Africa, who make up around 70% of all malaria deaths worldwide.1See the WHO fact sheet on malaria, which states “Globally in 2024, there were…
-
Podcast Episode 29: Behind the Analysis — Assessing Past Malaria Nets Grants
GiveWell’s research doesn’t end once we’ve made a grant. We evaluate a subset of completed grants, comparing what we thought would happen to what actually took place, then try to use what we learn to improve our future funding decisions. Over the past year, we’ve formalized and expanded this work, publishing comprehensive “lookbacks” for select…
-
GiveWell Opens RFI for Malaria Pilots and Research
GiveWell is launching a new request for information (RFI) to expand and strengthen our malaria grantmaking in Africa and help our donors make a greater impact. Expressions of interest can be submitted through one of two tracks, the first for malaria chemoprevention and vector control pilot programs and the second for research and evaluation. Submissions…
-
More than a Spoonful of Medicine
What does it take to prevent malaria? Some of the programs GiveWell recommends might sound straightforward—for example, seasonal malaria chemoprevention (SMC) programs provide antimalarial drugs to young children—but the process of accomplishing this is not simple at all. Below, we offer a post from Malaria Consortium that describes the many complex steps required to carry…
-
Why GiveWell funded the rollout of the malaria vaccine
Since our founding in 2007, GiveWell has directed over $600 million to programs that aim to prevent malaria, a mosquito-borne disease that causes severe illness and death. Malaria is preventable and curable, yet it killed over 600,000 people in 2021—mostly young children in Africa.[1] Following the World Health Organization’s approval of the RTS,S/AS01 malaria vaccine…
-
IPTi for malaria: a promising intervention with likely room to scale
Summary Intermittent preventive treatment in infants (IPTi) for malaria provides preventive antimalarial medicine to children under 12 months old. It is among the most promising programs we’ve identified in our active pipeline of new interventions. Not only does IPTi appear to be highly effective at reducing clinical malaria, it’s also underutilized (more below), and the…
-
Initial thoughts on malaria vaccine approval
The World Health Organization (WHO) recently recommended the widespread use of the malaria vaccine RTS,S/AS011We’ll use “RTS,S” as shorthand in this post. jQuery(‘#footnote_plugin_tooltip_13408_1_1’).tooltip({ tip: ‘#footnote_plugin_tooltip_text_13408_1_1’, tipClass: ‘footnote_tooltip’, effect: ‘fade’, predelay: 0, fadeInSpeed: 200, delay: 400, fadeOutSpeed: 200, position: ‘top right’, relative: true, offset: [10, 10], }); for children. It provides an additional, effective tool to…